SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

Recent Analyst Ratings for
$DICE

$DICE
Insider Trading

$DICE
SEC Filings

$DICE
Market Insights

$DICE
Leadership Updates

$DICE
Large Ownership Changes

Chat with this insight

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Ra Capital Management, L.P.

SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company

SEC Form 4 filed by Simson Jake

SEC Form 15-12G filed by DICE Therapeutics Inc.

SEC Form EFFECT filed by DICE Therapeutics Inc.

SEC Form S-8 POS filed by DICE Therapeutics Inc.

Live Market Insights

What 9 Analyst Ratings Have To Say About DICE Therapeutics

Top 5 Health Care Stocks That May Crash In Q3

MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022

Live Leadership Updates

ShouTi Appoints Sharon Tetlow to Board of Directors

DICE Therapeutics Expands Management Team and Board of Directors

This live feed shows all institutional transactions in real time.

6/22/23 4:32:29 PM ET

$DICE

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DICE alert in real time by email

SC 13D/A 1 d499106dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

DICE Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23345J104

(CUSIP Number)

Jonathan Goodman

Sands Capital Ventures, LLC

1000 Wilson Blvd., Suite 3000, Arlington VA 22209

Telephone: (703) 562-4000

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

June 20, 2023

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 23345J104


1.		Name of Reporting Persons. Sands Capital Global Venture Fund II, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization State of Delaware

(1)

The calculation of beneficial ownership of the Reporting Persons (as defined below) is based on 47,728,381 shares of Common Stock issued and outstanding as of May 3, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2023.

CUSIP No. 23345J104


1.		Name of Reporting Persons. Sands Capital Life Sciences Pulse Fund, LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization State of Delaware

(1)

CUSIP No. 23345J104


1.		Name of Reporting Persons. Sands Capital Life Sciences Pulse Fund II, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands

(1)

CUSIP No. 23345J104


1.		Name of Reporting Persons. Sands Capital Private Growth Fund III-DC, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

CUSIP No. 23345J104


1.		Name of Reporting Persons. Frank M. Sands
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.		SEC USE ONLY
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States of America

(1)

This includes 541,688 shares of Common Stock that are directly owned by Sands Capital Global Venture Fund II, L.P. (“Sands Venture Fund II”), 401,546 shares of Common Stock that are directly owned by Sands Capital Life Sciences Pulse Fund, LLC (“Sands Pulse Fund”), 596,694 shares of Common Stock that are directly owned by Sands Capital Life Sciences Pulse Fund II, L.P. (“Sands Pulse Fund II”), and 346,542 shares of Common Stock that are directly owned by Sands Capital Private Growth Fund III-DC, L.P. (“Sands Growth Fund”). Sands Capital Global Venture Fund II-GP, L.P. (“Sands Venture GP L.P.”) is the sole general partner of Sands Venture Fund II and Sands Growth Fund, and Sands Capital Global Venture Fund II-GP, LLC (“Sands Venture GP LLC”) is the general partner of Sands Venture GP L.P. Sands Capital Life Sciences Pulse Fund II-GP, L.P. (“Sands Pulse GP L.P.”) is the sole general partner of Sands Pulse Fund II, and the sole general partner of Sands Pulse Fund GP L.P. is Sands Capital Life Sciences Fund II-GP, LLC (“Sands Capital GP LLC”). Frank M. Sands holds ultimate voting and investment power over securities held by Sands Venture Fund II, Sands Pulse Fund, Sands Pulse Fund II, Sands Growth Fund, Sands Venture GP L.P., Sands Venture GP LLC, Sands Pulse GP L.P., and Sands Capital GP LLC, and therefore may be deemed to beneficially own a total of 1,886,470 shares of Common Stock.

(2)

This Amendment No. 1 to Schedule 13D relates to the common stock, par value $0.001 per share (the “Common Stock”), of DICE Therapeutics, Inc. (the “Issuer”), and amends the initial statement on Schedule 13D filed by the Reporting Persons on September 27, 2021 (the “Initial Statement”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Initial Statement.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Initial Statement is hereby amended and restated as follows:

(a) – (b) The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Persons is provided as of June 21, 2023:


Reporting Person	Securities Held Directly		Sole Voting Power		Shared Voting Power		Sole Dispositive Power		Shared Dispositive Power		Beneficial Ownership		Percentage of Class (1)
Sands Venture Fund II		541,688		0		541,688		0		541,688		541,688		1.1	%
Sands Pulse Fund		401,546		0		401,546		0		401,546		401,546		0.8	%
Sands Pulse Fund II		596,694		0		596,694		0		596,694		596,694		1.3	%
Sands Growth Fund		346,542		0		346,542		0		346,542		346,542		0.7	%
Frank M. Sands (2)		0		0		1,886,470		0		1,886,470		1,886,470		4.0	%

(1)	The percentages are based on 47,728,381 shares of Common Stock issued and outstanding as of May 3, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2023.

(2)

This includes 541,688 shares of Common Stock that are directly owned by Sands Venture Fund II, 401,546 shares of Common Stock that are directly owned by Sands Pulse Fund, 596,694 shares of Common Stock that are directly owned by Sands Pulse Fund II, and 346,542 shares of Common Stock that are directly owned by Sands Growth Fund. Sands Venture GP L.P. is the sole general partner of Sands Venture Fund II and Sands Growth Fund, and Sands Venture GP LLC is the general partner of Sands Venture GP L.P. Sands Pulse GP L.P. is the sole general partner of Sands Pulse Fund II., and the sole general partner of Sands Pulse Fund GP L.P. is Sands Capital GP LLC. Frank M. Sands holds ultimate voting and investment power over securities held by Sands Venture Fund II, Sands Pulse Fund, Sands Pulse Fund II, Sands Growth Fund, Sands Venture GP L.P., Sands Venture GP LLC, Sands Pulse GP L.P., and Sands Capital GP LLC, and therefore may be deemed to beneficially own a total of 1,886,470 shares of Common Stock.

(c) On June 20, 2023 the Reporting Persons sold an aggregate of 345,000 shares of Common Stock in open market transactions at a price of $46.46 per share for aggregate consideration of $16,028,700. In the transactions, Sands Venture Fund II sold 99,064 shares, Sands Pulse Fund sold 73,436 shares, Sands Pulse Fund II sold 109,124 shares and Sands Growth Fund sold 63,376 shares.

On June 21, 2023 the Reporting Persons sold an aggregate of 517,500 shares of Common Stock in open market transactions at a price of $46.57 per share for aggregate consideration of $24,099,975. In the transactions, Sands Venture Fund II sold 148,596 shares, Sands Pulse Fund sold 110,154 shares, Sands Pulse Fund II sold 163,686 shares and Sands Growth Fund sold 95,064 shares.

(d) Inapplicable.

(e) As a result of the transactions described herein, on June 21, 2023 the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding Common Stock.

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 22, 2023


Sands Capital Global Venture Fund II, L.P.

By:		Sands Capital Global Venture Fund II-GP, L.P., its general partner

By:		Sands Capital Global Venture Fund II-GP, LLC, its general partner

By:		/s/ Jonathan Goodman
		Name: Jonathan Goodman
		Title: General Counsel

Sands Capital Life Sciences Pulse Fund, LLC

By:		/s/ Jonathan Goodman
		Name: Jonathan Goodman
		Title: General Counsel

Sands Capital Life Sciences Pulse Fund II, L.P.

By:		Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner

By:		Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner

By:		/s/ Jonathan Goodman
		Name: Jonathan Goodman
		Title: General Counsel

[Signature Page to Schedule 13D]


Sands Capital Private Growth Fund III-DC, L.P.

By:		Sands Capital Global Venture Fund II-GP, L.P., its general partner

By:		Sands Capital Global Venture Fund II-GP, LLC, its general partner

By:		/s/ Jonathan Goodman
		Name: Jonathan Goodman
		Title: General Counsel

By:		/s/ Frank M. Sands
		Name: Frank M. Sands

[Signature Page to Schedule 13D]

Get the next $DICE alert in real time by email

Date	Price Target	Rating	Analyst
5/24/2023	$38.00	Equal Weight	Wells Fargo
5/22/2023	$71.00	Buy	Canaccord Genuity
3/31/2023	$56.00	Buy	Needham
3/1/2023		Outperform	TD Cowen
3/1/2023		Outperform	Cowen
11/15/2022	$65.00	Buy	Guggenheim
9/14/2022	$36.00	Overweight	Cantor Fitzgerald
9/7/2022	$37.00	Buy	Stifel

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

Sole Voting Power

0

Shared Voting Power

541,688

Sole Dispositive Power

0

Shared Dispositive Power

541,688